06.13.26 -- Focusing On Process Performance, The State of The Industry, And Simplifying Downstream Unit Operations

Happy Saturday! This week, I’d like to direct attention to some exciting projects we have cooking at Bioprocess Online. We host virtual Live events almost every month, which are always available to watch on demand. In May, our expert panelists discussed the factors limiting downstream viral vector recovery and the strategies manufacturers are using to balance yield, product quality, scalability, and cost.

On June 16, we’ll explore the various levers and tradeoffs that drive process productivity with David Scherr, Ph.D., a senior scientist at AstraZeneca, and Vadim Klyushnichenko, Ph.D., the VP biopharmaceutical development and quality at Calibr-Skaggs Institute for Innovative Medicines. Register for free to join us live or to be notified when the recording is available to watch on demand!

I was recently joined by my colleagues from across the Life Science Connect publishing sphere on “Better Biopharma” to discuss industry developments and share predictions for what the rest of 2026 has in store. Give that a listen wherever you get your podcasts, and if you’re a fan of the show, we’d love to hear from you! Take this short survey and let us know how we can improve our coverage.

Before you go, check out some selected content from our partners below!

Tyler Menichiello                           
Chief Editor, Bioprocess Online

Lonza shares practical strategies for overcoming ADC manufacturing complexity, streamlining tech transfer, and advancing high-potency bioconjugates.

INFORS HT helps laboratories maintain consistent air quality, reducing contamination risk during active workflows with continuous filtration, validated performance, and stability.

Roche CustomBiotech highlights ways to fine-tune IVT reactions, from magnesium balance to template optimization, helping teams improve mRNA process consistency.

QIAGEN explores smarter approaches to DNA clearance in viral vector manufacturing with strategies that improve purity and support regulatory confidence.

MilliporeSigma intensifies mAb processing with integrated analytics, automation, and scalable workflows to boost productivity, cut costs, and future-proof operations.

RoosterBio outlines a scalable approach to exosome purification that boosts recovery, improves purity, and preserves therapeutic quality—examine how.

Minaris demystifies QC strategies for biologics, from traditional mAbs to advanced therapies, assisting teams in testing, managing risk, and building scalable programs.